A common gene change is tied to higher levels of one immune target in grade 4 brain tumors
Original title: TP53 mutation is associated with selective upregulation of LAG3 independent of immune infiltration and antigen-presentation signatures in WHO grade 4 glioma.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was done on cells in a lab, not in people. It is a very early step.
This only looked at gene data from tumors already collected, not a treatment given to people.
The short version
In grade 4 brain tumors, a common gene change came with more of one immune marker called LAG3.
What was studied. Researchers used stored gene data from tumors of people with CNS WHO grade: A number from 1 to 4 for how a tumor is likely to behave. Since 2021 it is written in plain numbers, not Roman ones. Gene results can set it too. See the glossary 4 glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are given a grade from 1 to 4 describing how the tumor is expected to behave. See the glossary. They studied 442 tumors first, then checked 79 more. They compared 7 genes that act as brakes on the immune system in tumors with and without a change in the TP53: A gene checked on the tumor tissue. Whether it has changed is one of the findings used to name an astrocytoma. Ask your team whether the change they found was in the tumor only. See the glossary gene.
What they found. Tumors with the TP53: A gene checked on the tumor tissue. Whether it has changed is one of the findings used to name an astrocytoma. Ask your team whether the change they found was in the tumor only. See the glossary change had more LAG3 activity. Of the 7 genes tested, only LAG3 showed this pattern. The same pattern showed up again in the 79 tumors checked second. The link held even after the team accounted for how much immune activity each tumor had.
What this means, and what it doesn't
What it could mean: LAG3 is a target that some newer cancer drugs aim at. If this holds up, a TP53: A gene checked on the tumor tissue. Whether it has changed is one of the findings used to name an astrocytoma. Ask your team whether the change they found was in the tumor only. See the glossary test might one day help pick who could try a LAG3 drug. Right now it is only a lead for more research.
What it doesn't mean: This does not mean there is a new treatment. No one was given a drug in this study. The team only looked at gene data from tumors that were already collected. No one lived longer or felt better because of this work. It is not a promise of a cure. Doctors cannot use it to change care today.
Source: PubMed, September 3, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.